AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-01
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(1) · ALS(2) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
- Abstract
Sequence-to-function models are increasingly used as oracles to score designed regulatory elements, on the untested assumption that an effect measured at one locus holds at another. Taking chromatin and host loci from multiple sclerosis risk regions, we kept four questions apart: sequence realism, transfer of discrimination, edit stability, calibration. A sixth-order Markov chain reproduced the cell-type-specific motif enrichment a trained transformer missed, despite its lower held-out likelihood. Scores differ in level between loci far more than between inserts at one locus, yet inserts selected by an Enformer-derived index kept 85% of their advantage at four unseen loci. Once GC was matched, however, the index separated peak-derived from inaccessible sequence at none of 12 hosts, and from random sequence in opposite directions at different hosts. Placing identical inserts and an identical CpG edit at 24 host loci, the effect varied far beyond sampling noise on host identity alone ([Formula: see text]), unpredicted by 18 host properties. It survives scoring only the bins the insert occupies ([Formula: see text], and across 200 loci), so is no artefact of aggregation; the apparent host dominance, however, falls from 25-fold to 3-fold under that localised score, and the one locus positive under the whole-window score reverses under it. Borzoi reproduced the heterogeneity but not its amplitude, and the objective did not predict lentiMPRA activity. For these two oracles and this edit, the size of a predicted effect depends on where it is measured, and its direction at any one locus is not robust.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-10-31, retrieved 2026-11-01; not the official Clarivate IF)Reference: Uysal SA. Host genomic context determines the direction of an oracle-predicted sequence effect: a composition-preserving CpG intervention in Enformer and Borzoi. Funct Integr Genomics. 2026 Oct 31;26(1):310. doi:10.1007/s10142-026-02097-3. PMID: 42963434.Checked: Abstract only
See all 1 Basic research papers →
ALS: treatment, trials and AI
- Abstract
BACKGROUND: Motor neuron disease (MND) is a devastating and fatal neurodegenerative disease with limited treatment options. Diagnosis is hampered by the lack of definitive and reliable investigations. Dysarthria is a common early symptom, but current methods for assessing speech are crude, subjective and burdensome. Speech processing and artificial intelligence (AI) can offer objective, reliable and scalable assessments with low-burden and patient-centred digital technologies. OBJECTIVES: Describe existing work in speech processing methods to assess dysarthria in MND. Develop a patient-centred and user-friendly speech recording app for people living with MND. Collect and curate a longitudinal speech dataset with detailed demographic, language background and clinical annotations. Assess the usability and acceptability of the proposed assessment methods. Develop deep learning models for dysarthria severity assessment, and clinically evaluate their validity, reliability and utility in diagnosis and monitoring. Assess potential biases and confounding factors in a digital speech biomarker for MND. METHODS: A systematic literature review of speech processing and digital speech biomarkers in MND was conducted. A speech recording app, co-produced with people living with MND and their caregivers, was deployed in observational studies recruiting MND and neurologically healthy control groups. Assessments included six speech tasks and digital outcome measures with concurrent clinical assessments, including the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) and cognitive tests. The usability and acceptability of the app assessments were examined through participant feedback. 20 deep learning speech embeddings were benchmarked; the best were used to train a novel model via scalar ordinal triplet learning. The clinical validity and reliability of the novel model were evaluated in a held-out test set, and externally validated in German (DZNE Rostock) and Taiwanese (VoiceBank-2023) datasets, with results pooled using random effects models. Confounding bias was assessed using a silence-based ablation study and regression-based statistical adjustment for demographic and recording-related variables. Clinical correlations were evaluated against functional, cognitive and quality of life measures. Progression modelling used linear mixed-effects models to estimate individual trajectories, identify heterogeneous progression sub-groups, and assess the predictive value of baseline assessments for future rates of decline. RESULTS: A total of 298 participants (115 with MND, 183 controls) contributed to the speech corpus across 540 assessments, with 91 (31%) contributing longitudinally for up to 3 years. Participants were representative of the broader MND population. The speech assessment procedure received positive feedback, showing good to excellent usability and acceptability. Deep learning speech embeddings outperformed conventional acoustic features in classifying diagnosis. The proposed model was evaluated across internal and external datasets (254 speakers: 136 with MND, 118 controls). Classification performance for MND diagnosis and dysarthria detection was excellent, with pooled AUCs of 0.905 (95% CI [0.706, 0.974]) and 0.937 (95% CI [0.859, 0.973]) respectively, and was significantly associated with the ALSFRS-R speech subscore (β = 0.552, 95% CI [0.274, 0.830]). Reliability was excellent (internal consistency α = 0.989; test-retest ICC = 0.829). The model generalised well to external datasets of different languages after calibration with only 10 control speakers, outperforming conventional supervised models on all measures and showing superior reliability to the ALSFRS-R speech subscore. Confounding bias assessment demonstrated robustness against demographic and recording-related variables. Model predictions correlated with ALSFRS-R bulbar (β = 1.510, p < 0.001) and total (β = 2.314, p = 0.005) scores; and EQ-5D-5L quality of life domains (p < 0.01), but not with non-bulbar ALSFRS-R domains or cognitive function. Bulbar onset was associated with worse baseline speech function (Cohen’s d = -1.011, p = 0.011) and faster progression (Cohen’s d = -0.931, p = 0.026) than limb onset. Progression modelling identified stable fast and slow progressing subgroups (H = 33.94, p < 0.001), with baseline assessments predicting subsequent dysarthria decline (Cohen’s f² = 2.118, permutation test p < 0.001). CONCLUSION: Patient-centred digital speech assessments are scalable, robust and well-accepted by people with MND. The proposed deep learning model outperformed supervised methods by leveraging weakly labelled data to learn dysarthria severity relationships, yielding superior clinical validity and reliability compared to existing scales. The model generalises across languages after minimal calibration and confounding analysis confirmed it captures disease-relevant speech signals rather than spurious correlations. Clinical correlations and progression modelling further support the model’s construct validity in monitoring within-individual speech decline. These findings establish our proposed model as a state-of-the-art digital speech biomarker for MND, with applications in early detection, prognostication, progression monitoring, and clinical trials. This work represents a significant step towards clinical deployment. Future directions include prospective and multi-centre validation, multilingual expansion, integration into care pathways, and extension to other neurodegenerative disorders.
Journal IF: unknown (could not be matched)Reference: [No authors listed]. Deep learning digital speech biomarkers in motor neuron disease. University of Edinburgh. [Epub ahead of print]. doi:10.7488/era/7947.Checked: Abstract only - Abstract
Background: Electromyogram (EMG) is considered for the diagnosis of amyotrophic lateral sclerosis (ALS). We investigated how frequently an initial electrophysiological evaluation is performed in ALS patients.
Objective: We aimed to identify ALS cases using the feature selection algorithm (FSA). A pattern of feature involvement was expected in the early phase of ALS based on the typical consistent involvement of a few particular muscles in the late stages.
Methods: We used a clinical and EMG dataset of 36 patients (21 ALS patients and 15 healthy) for analysis. The present approach used a Random Forest (RF)-based machine learning (ML) algorithm for the prediction of ALS patients. The goal of this study was to determine how feature selection techniques can enhance machine learning algorithms that can be used in real-time applications.
Findings: The experimental findings demonstrate the superior performance of the proposed model. This work demonstrates how machine learning models can offer important predictive insights in ALS, improving knowledge of disease dynamics and aiding patient care. According to the comparison results, the RF model utilizing the feature selection algorithm demonstrated a positive improvement, and the accuracy of the RF model with and without the feature selection technique was found to be 87.50% and 75%, respectively.
Conclusions: The algorithm improved the model accuracy from 75% to 87.50%, resulting in an absolute increase of 12.5 percentage points in classification accuracy. This study found that fibrillation, positive sharp waves (PSW), and fasciculation features were high-yielding in EMG of ALS cases.
Journal IF-equivalent: 4.0 (OpenAlex 2-year mean citedness, value as of 2026-10-16, retrieved 2026-10-17; not the official Clarivate IF)Reference: Dutt A, Tiwari A, Tripathi S, Tiwari PK, Kumar M, Dwivedi A, et al. Enhancing Machine Learning Performance for ALS Classification Using Feature Selection Technique. Diagnostics. 2026 Oct 29;16(21):3573. doi:10.3390/diagnostics16213573.Checked: Abstract only
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
This systematic review and meta-analysis aimed to evaluate the performance of deep learning (DL)-based methods for classifying individuals with Parkinson’s disease (PD) from handwriting and drawing tasks, following PRISMA guidelines. Google Scholar, IEEE Xplore, PubMed/MEDLINE, ScienceDirect, and Science.gov were searched from 1 July to 17 July 2026, without publication date restrictions. Eligible studies evaluated a DL architecture for PD detection using handwriting or drawing and reported at least one of five performance metrics: accuracy, sensitivity, specificity, precision, or F1-score. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment using PROBAST+AI. Performance estimates were logit-transformed and pooled separately using random-effects models. Heterogeneity was assessed using Cochran’s Q, I2, and τ2, and results were presented using forest plots with 95% confidence intervals. Potential sources of heterogeneity were investigated through subgroup analyses according to DL architecture, dataset, task, and validation procedure, together with sensitivity analyses. Publication bias was assessed using Egger’s test, and certainty of evidence was evaluated using GRADE. Of 5233 unique records identified, 30 studies were included. Overall pooled performance exceeded 92% across the evaluated metrics. No significant differences were found between fully DL and hybrid approaches or among DL algorithms. Dataset-related differences were observed but were inconsistent across performance metrics. Combined handwriting and drawing tasks consistently achieved higher performance (>95%) than individual tasks, while cross-validation was associated with higher accuracy, specificity, and sensitivity than hold-out validation. Despite these promising findings, substantial heterogeneity and very low certainty of evidence limit the current clinical applicability of these approaches. More standardized protocols, subject-level data separation, and external validation in independent populations are needed to develop robust and generalizable AI models and clarify the potential of handwriting and drawing as non-invasive tools for PD detection.
Journal IF-equivalent: 6.0 (OpenAlex 2-year mean citedness, value as of 2026-10-31, retrieved 2026-11-01; not the official Clarivate IF)Reference: Gorce P, Jacquier-Bret J. Diagnostic Performance of Artificial Intelligence for Parkinson’s Disease Detection Using Handwriting and Drawing Tasks: A Systematic Review and Meta-Analysis. Sensors. 2026 Oct 30;26(21):6893. doi:10.3390/s26216893.Checked: Abstract only - Abstract
Background: Parkinson’s disease (PD) requires both disease-specific knowledge and contextual clinical reasoning. However, most evaluations of medical large language models (LLMs) emphasize closed-ended questions and factual accuracy, providing limited insight into broader dimensions of performance on professional PD tasks.
Methods: Nine contemporary LLMs were evaluated using a 200-item English-language professional PD benchmark spanning five clinical domains, four difficulty levels, and multiple question formats. Responses were assessed for expert-rated factual accuracy, clinical reasoning, Global Quality Scale (GQS), and Flesch–Kincaid Grade Level (FKGL).
Results: The nine models generated 1,800 responses. Between-model separation was minimal for expert-rated factual accuracy (Kendall’ s W = 0.031) but greater for FKGL (W = 0.235), Clinical Reasoning (W = 0.256), and GQS (W = 0.301). Between-model separation in expert-rated factual accuracy was small for closed-ended questions (W = 0.020, p = 0.001) but greater for open-ended questions (W = 0.121, p < 0.001). Expert-rated factual accuracy remained weakly discriminative across PD domains and difficulty levels, while GQS showed the greatest domain-specific separation in Safety & Ethics (W = 0.431). Flagship variants consistently showed higher Clinical Reasoning and GQS, but not uniformly higher factual accuracy.
Conclusion: Contemporary LLMs showed limited between-model separation in expert-rated factual accuracy within this benchmark and scoring framework, whereas greater differentiation emerged in open-ended tasks, clinical reasoning, overall response quality, and readability. Multidimensional evaluation may therefore provide a more informative characterization of model performance and help inform task-specific model selection and oversight in medical applications.
Journal IF-equivalent: 3.1 (OpenAlex 2-year mean citedness, value as of 2026-10-07, retrieved 2026-10-08; not the official Clarivate IF)Reference: Xie L, Wei R, Xiong L, Lu R, Peng K, Ma W. Comparative performance of nine large language models on professional Parkinson’s disease tasks: a multidimensional benchmark study. Front Neurol. 2026 Oct 30;17:1970459. doi:10.3389/fneur.2026.1970459.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
- Abstract
Multiple Sclerosis (MS) is an immune-mediated central nervous system condition with heterogeneous clinical manifestations, progressive neurodegeneration, and considerable variability in disease trajectory. Recent advances in artificial intelligence (AI), particularly machine learning (ML) methods, have improved MS diagnosis and risk prediction. However, comprehensive review studies emphasizing the potential of existing AI-powered MS diagnosis remain limited. Thus, this study investigates the utilization of multimodal data by AI models to enhance diagnostic accuracy, evaluate disease progression, and optimize personalized care strategies. By adhering to PRISMA guidelines, this review included 26 studies encompassing MRI-based analysis, retinal OCT imaging, blood transcriptomics, SNP genotyping, and multimodal clinical datasets. An additional classification of these studies by modality was performed, and they were assessed with respect to dataset size, performance metrics, biomarkers, methodological robustness, and model interpretability. The findings indicate a consistent trend toward outstanding diagnostic performance, with some AI models achieving accuracies exceeding 95% using medical imaging and genomic data. However, limited external validation and interpretability procedures create a gap in clinical applicability and trustworthiness. This review highlights AI's growing potential to revolutionize MS diagnosis.
Journal IF-equivalent: 2.6 (OpenAlex 2-year mean citedness, value as of 2026-10-08, retrieved 2026-10-09; not the official Clarivate IF)Reference: Wahab Sait AR, Alkhurayyif Y. Artificial intelligence-driven multiple sclerosis diagnosis using genomic and medical imaging data: a review. Front Med. 2026 Oct 29;13:1812134. doi:10.3389/fmed.2026.1812134.Checked: Abstract only
See all 1 Multiple sclerosis papers →
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.